Certain HPV16 antibodies may predict oropharyngeal cancer survival
the ONA take:
Certain human papillomavirus (HPV)-16 antibodies in the blood was associated with improved survival rates among patients with HPV-related oropharyngeal carcinoma, according to a new study.
For the study, researchers analyzed blood samples from 209 patients with previously untreated oropharyngeal carcinoma. Of those, 96 had confirmed HPV-positive disease. Samples were screened for HPV16 antibodies E1, E4-7, L1, L2, and the N-terminal and C-terminal fragments of E2.
Results showed that patients with any of the E antibodies had improved overall and progression-free survival versus those who tested negative for the antibodies. HPV-positive patients who tested positive for NE2, E1, or E6 antibodies also had a reduced mortality and disease progression risk.
Researchers found no survival advantage for people who tested positive for L antibodies.
Clinical trials are currently ongoing to evaluate whether vaccines can stimulate these antibodies to improve outcomes in patients with HPV-related cancers.
Certain HPV-16 antibodies in the blood associated with improved survival in HPV-related oropharyngeal carcinoma.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|